NCT04044313View on ClinicalTrials.gov

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

February 1, 2021

Study Completion Date

February 28, 2022

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

Hepatic arterial infusion chemotherapy

administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks

DRUG

Lenvatinib

12 mg (or 8 mg) once daily (QD) oral dosing.

DRUG

Toripalimab

240mg intravenously every 3 weeks

Trial Locations (1)

510060

Cancer Center Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Shi Ming

OTHER

NCT04044313 - HAIC Plus Lenvatinib and Toripalimab for Advanced HCC | Biotech Hunter | Biotech Hunter